Preeclampsia Diagnostics Market, By Test Type (Blood Tests, Urine Analysis, Others), By Product Type (Instruments and Consumables), By End User (Hospital, Specialty Clinics, Diagnostic Centers, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jun 2024

Code : CMI4606

Pages :188

Formats :

Excel and PDF

Industry : Clinical Diagnostic

Key Developments

On January 31, 2024, Labcorp, provider of laboratory services, has launched an USFDA-cleared blood test for severe preeclampsia risk assessment and management. Developed by Thermo Fisher Scientific, the test measures two biomarkers associated with preeclampsia and was named one of TIME Magazine's Best Inventions of 2023.
In July 2023, An USFDA-approved blood test, developed by Thermo Fisher Scientific, pharmaceutical and biotechnology company accurately predicts preeclampsia within two weeks with a 96% success rate. Praised by experts such as Dr. Douglas Woelkers from the University of California, San Diego, it marks a notable advancement in preeclampsia diagnostics.
In May 2023, CSEM, a technology innovation center, its Tools for Life Sciences division is collaborating with MOMM Diagnostics, company which develops a rapid diagnostic test for the detection of preeclampsia - a dangerous pregnancy condition. to create an innovative point-of-care solution for preeclampsia diagnosis. This advanced sensing device simultaneously identifies two key biomarkers linked to this common condition, representing a significant breakthrough in diagnostics.
In July 2021, LifeCell Diagnostics, a biotechnology company introduced a comprehensive preeclampsia screening program in India. This initiative aims to detect the biomarker sFLT-1 (soluble FMS-like tyrosine kinase-1), enabling early prediction and accurate diagnosis of the condition, even during the third trimester of pregnancy.